Information  X 
Enter a valid email address

Futura Medical PLC (FUM)

  Print      Mail a friend       Annual reports

Monday 22 March, 2021

Futura Medical PLC

US FDA Agreement for Confirmatory Clinical study

RNS Number : 9463S
Futura Medical PLC
22 March 2021
 

 

22 March 2021

Futura Medical plc

Futura Medical Receives US FDA Agreement for
Confirmatory Clinical study, FM71 for MED3000

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that it has received  official minutes from the US Food and Drug Administration (FDA) for MED3000, the Company's breakthrough fast acting clinically proven treatment for erectile dysfunction ("ED"), following its 4th Pre-Submission Meeting on 1st February 2021.

 

The minutes signify agreement between the FDA and Futura on the detailed clinical study design (protocol) for the small confirmatory clinical study, FM71, to be conducted prior to formal regulatory submission as a DeNovo Medical Device. Detailed planning for the commencement of FM71 has now begun with first patient dosing expected H2 2021.

 

FM71 is designed to provide supplementary efficacy data to the previously reported FM57 study with a "least burdensome" approach and modest cost. Whilst the overall design is similar to that of the previous large phase 3 FM57 study that recruited approximately 1000 patients, no placebo (sham) cohort is required, hence the study is relatively smaller in size with approximately 100 patients.

 

FM71 will be a 6 month (24 weeks) duration study versus FM57 which was conducted over 3 months (12 weeks) to reassure the FDA that the efficacy does not diminish over a longer period of time. It is Futura's belief that this is unlikely as in the FM57 study efficacy improved from the first to third month of patient use. Two co-primary endpoints will measure the significant clinically meaningful effect as calculated using the Rosen and Araujo statistical method, a standard assessment technique for measuring Patient Reported Outcomes, which was also used in study FM57 in which MED3000 exceeded the minimal clinically important difference as defined by Rosen et al. Both will use the International Index of Erectile Function (IIEF-EF domain); an internationally recognised and fully validated measure used in gold-standard ED clinical trials. The first co-primary endpoint measures IIEF-EF change from baseline which was highly significantly improved at 12 weeks in FM57, and the second endpoints requires a minimum change in improvement from baseline of 4 IIEF-EF units (where a 5.1 change was achieved in FM57). Secondary endpoints include an agreed measure of speed of onset, a key differentiating claim, where FM57 showed that 60% of subjects noticed an erection within 10 minutes.

 

The Company has agreed with the FDA to include tadalafil (Cialis®) at the lowest approved dose for on-demand use (5mg) for comparative purposes only on safety, speed of onset and efficacy; non-inferiority is not required to be shown.

 

FM71 is designed as a phase 3, multicentre, comparative, randomised, open-label, home use, parallel group study.  The recruited patients will include those suffering from mild, moderate or severe ED, using either MED3000 or tadalafil 5mg (50 subjects per group) and will also include 20 African American patients (from a US medical centre) and 80 patients recruited from Eastern Europe where sites include some of the same centres used in the FM57 study. The Company is also pleased to confirm that the Co-ordinating (Principal) Investigator will be world-renowned Professor Arthur Burnett, MD, MBA, FACS, Distinguished Professor of Urology, Johns Hopkins School of Medicine, Brady Urological Institute. Professor Burnett is also a past President of the Sexual Medicine Society.

 

Professor Burnett commented: "In my humble opinion and as an expert in the field of erectile dysfunction management, I am very supportive of MED3000 and do believe that it offers an important and valid addition to the armamentarium of treatments we can offer our patients for erectile dysfunction. I am very pleased to support Futura Medical in the further clinical investigation of this novel topical treatment."

 

James Barder, Chief Executive of Futura Medical commented: "We are pleased to have reached agreement with the FDA on the clinical trial protocol for FM71 which follows closely the positive recommendation for approval from the Notified Body on the European submission for MED3000, and the recently announced Joint Collaboration agreement for the China and South East Asia region. These key milestones are indicative of the rapid progress we have made in the last few months on our journey to fully commercialise MED3000."

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

 

 

-ENDS-

 

For further information please contact:

 

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [email protected]

Tel: +44 (0) 1483 685 670

www.futuramedical.com

 

Nominated Adviser and Sole Broker:

 

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [email protected]

Tel: +44 (0) 203 922 0890

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.  

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.  www.futuramedical.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDDGDXIBDDGBB

a d v e r t i s e m e n t